Bayer Settles 70 Product Liability Claims Involving Two of its Oral Contraceptives
Pharmaceutical giant Bayer has agreed to settle 70 of the more than 11,000 product liability claims involving two of its top-selling oral contraceptives—Yaz and Yazmin, according to its latest annual report. The mounting lawsuits from women worldwide allege that the two drugs (or their generic versions—Ocella and Gianvi) cause serious and potentially life-threatening injuries.
Both Yaz and Yasmin contain drospirenone, a progestin hormone that has the inherent ability to alter the conditions in the cervical and uterine lining, therefore preventing ovulation. However, members of a recent Federal Drug Administration (FDA) Advisory Committee opined that Yaz and similar drospirenone-containing contraceptives may heighten potassium levels. Significantly elevated potassium levels may result in the development of severe blood clots. If a blood clot develops in an artery leading to the brain, it could cause a stroke or possible death.
In December of 2011, The New York Times reported that an advisory committee to the FDA recommended that the labels on Yaz and Yasmin be strengthened to include more information about the possibility that the pills could lead to greater risk of blood clots in women.
“Consumers beware—that’s the message here,” says Howard Krepack, partner with the law firm of Gordon, Edelstein, Krepack, Grant, Felton & Goldstein, LLP (GEK). “Although pharmaceutical companies should label their products thoroughly and responsibly, it is wise to do your homework before taking medications.”
GEK has had great success representing clients harmed by unsafe drugs, as well as clients injured by toxic substances. If you have concerns about Yaz or Yasmin, please contact us at 213-739-7000.